Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1271-1275

  Rotsos, Tryfon ^a   Patel, Praveen J ^a   Chen, Fred K ^a   Tufail, Adnan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Macular degeneration; Ranibizumab; Retina

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; FUNDING; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; TERTIARY HEALTH CARE; THERAPY DELAY; THROMBOEMBOLISM; TRAUMATIC CATARACT; UNITED KINGDOM; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 78650681789     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S14684     Document Type: Article

References (6)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
3. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
4. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148: 43-58.
5. Spaide R. Ranibizumab according to need: A treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679-680.
6. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148:409-413.